Bing C. Wang
Net worth: - $ as of 2024-03-30
Profile
Bing C.
Wang was the founder and held the position of Chief Executive Officer & Director at Refuge Biotechnologies, Inc. which was founded in 2016.
Dr. Wang also held the position of Director-Healthcare Investment Banking at Barclays Capital, Inc. Dr. Wang was a Director at KBP Biosciences USA, Inc. from 2017 to 2018.
Additionally, Dr. Wang served as the Chief Financial Officer at Cellectis SA from 2022 to 2024.
Dr. Wang's education includes an undergraduate degree from The Trustees of Columbia University in The City of New York, graduate and doctorate degrees from Princeton University, and an MBA from Columbia Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CELLECTIS SA
-.--% | 2023-02-13 | 0 ( -.--% ) | - $ | 2024-03-30 |
Former positions of Bing C. Wang
| Companies | Position | End |
|---|---|---|
| CELLECTIS S.A. | Director of Finance/CFO | 2024-05-01 |
Refuge Biotechnologies, Inc.
 Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Founder | 2021-11-30 |
KBP Biosciences USA, Inc.
 KBP Biosciences USA, Inc. Miscellaneous Commercial ServicesCommercial Services KBP Biosciences engages in conducting biotechnological research to develop therapies for patients. The company was founded by Huang Zhenhua in and is headquartered in Princeton, NJ. | Director/Board Member | 2018-09-30 |
Barclays Capital, Inc.
 Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Head of Private Banking | - |
Training of Bing C. Wang
| The Trustees of Columbia University in The City of New York | Undergraduate Degree |
| Princeton University | Doctorate Degree |
| Columbia Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CELLECTIS S.A. | Health Technology |
| Private companies | 3 |
|---|---|
Barclays Capital, Inc.
Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Finance |
KBP Biosciences USA, Inc.
KBP Biosciences USA, Inc. Miscellaneous Commercial ServicesCommercial Services KBP Biosciences engages in conducting biotechnological research to develop therapies for patients. The company was founded by Huang Zhenhua in and is headquartered in Princeton, NJ. | Commercial Services |
Refuge Biotechnologies, Inc.
Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Commercial Services |
- Stock Market
- Insiders
- Bing C. Wang